

# smart Health Report

An Insightful Health Analytics Report  
for Easier Understanding

Prepared For

**Mr Mr.Dummy**

**M 23**



| Name        | Patient ID | Gender | Age |
|-------------|------------|--------|-----|
| Mr Mr.Dummy | 8053280    | M      | 23  |

## Health Summary



### BLOOD COUNTS

Everything looks good



### LIPID PROFILE

Everything looks good



### DIABETES MONITORING

Everything looks good



### ANEMIA STUDIES

Everything looks good



### VITAMIN PROFILE

Everything looks good




|                   |                      |                  |                           |                                                                                                |
|-------------------|----------------------|------------------|---------------------------|------------------------------------------------------------------------------------------------|
| Patient Name      | : Mr Mr.Dummy        | Sample Collected | : Apr 26, 2024, 01:00 PM  | <br>MC-5280 |
| DOB/Age/Gender    | : 23 Y/Male          | Report Date      | : Jun 04, 2024, 01:58 PM. |                                                                                                |
| Patient ID / UHID | : 8053280/RCL7247928 | Barcode No       | : HY748008                |                                                                                                |
| Referred By       | : Dr. Dr. X          | Report Status    | : Final Report            |                                                                                                |
| Sample Type       | : Whole blood EDTA   |                  |                           |                                                                                                |
| Test Description  | Value(s)             | Unit(s)          | Reference Range           |                                                                                                |

Pollution Risk Assessment- Advanced

Complete Blood Count (CBC)

|                                            |          |               |             |
|--------------------------------------------|----------|---------------|-------------|
| RBC Parameters                             |          |               |             |
| Hemoglobin<br>colorimetric                 | 14.0     | g/dL          | 13.0 - 17.0 |
| RBC Count<br>Electrical impedance          | 4.7      | 10^6/ $\mu$ l | 4.5 - 5.5   |
| PCV<br>Calculated                          | 45       | %             | 40 - 50     |
| MCV<br>Calculated                          | 98       | fl            | 83 - 101    |
| MCH<br>Calculated                          | 29       | pg            | 27 - 32     |
| MCHC<br>Calculated                         | 32       | g/dL          | 31.5 - 34.5 |
| RDW (CV)<br>Calculated                     | 12       | %             | 11.6 - 14.0 |
| RDW-SD<br>Calculated                       | 37       | fl            | 35.1 - 43.9 |
| WBC Parameters                             |          |               |             |
| TLC<br>Electrical impedance and microscopy | 8        | 10^3/ $\mu$ l | 4 - 10      |
| Differential Leucocyte Count               |          |               |             |
| Neutrophils<br>Laser based Flow-cytometry  | 67       | %             | 40-80       |
| Lymphocytes<br>Laser based Flow-cytometry  | 30       | %             | 20-40       |
| Monocytes<br>Laser based Flow-cytometry    | 2        | %             | 2-10        |
| Eosinophils<br>Laser based Flow-cytometry  | 1        | %             | 1-6         |
| Basophils<br>Laser based Flow-cytometry    | 0        | %             | <2          |
| Blasts<br>Microscopy                       | Not seen | %             | -           |
| Band forms<br>Microscopy                   | Not seen | %             | -           |
| Promyelocytes<br>Microscopy                | Not seen | %             | -           |
| Myelocytes<br>Microscopy                   | Not seen | %             | -           |
| Metamyelocytes<br>Microscopy               | Not seen | %             | -           |



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI  
Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301

928-909-0609

ccsupport@redcliffelabs.com

www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

Patient Name : Mr Mr.Dummy  
 DOB/Age/Gender : 23 Y/Male  
 Patient ID / UHID : 8053280/RCL7247928  
 Referred By : Dr. Dr. X  
 Sample Type : Whole blood EDTA

Sample Collected : Apr 26, 2024, 01:00 PM  
 Report Date : Jun 04, 2024, 01:58 PM.  
 Barcode No : HY748008  
 Report Status : Final Report



| Test Description                                             | Value(s)                                                                        | Unit(s)             | Reference Range |
|--------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------|-----------------|
| Polymphocytes<br><i>Microscopy</i>                           | Not seen                                                                        | %                   | -               |
| <b>Absolute Leukocyte Counts</b>                             |                                                                                 |                     |                 |
| Neutrophils.<br><i>Calculated</i>                            | 5.36                                                                            | 10 <sup>3</sup> /μl | 2 - 7           |
| Lymphocytes.<br><i>Calculated</i>                            | 2.4                                                                             | 10 <sup>3</sup> /μl | 1 - 3           |
| Monocytes.<br><i>Calculated</i>                              | <b>0.16</b>                                                                     | 10 <sup>3</sup> /μl | 0.2 - 1.0       |
| Eosinophils.<br><i>Calculated</i>                            | 0.08                                                                            | 10 <sup>3</sup> /μl | 0.02 - 0.5      |
| Basophils.<br><i>Calculated</i>                              | <b>0</b>                                                                        | 10 <sup>3</sup> /μl | 0.02 - 0.5      |
| <b>Platelet Parameters</b>                                   |                                                                                 |                     |                 |
| Platelet Count<br><i>Electrical impedance and microscopy</i> | 215                                                                             | 10 <sup>3</sup> /μl | 150 - 410       |
| Mean Platelet Volume (MPV)<br><i>Calculated</i>              | 10.3                                                                            | fL                  | 9.3 - 12.1      |
| PCT<br><i>Calculated</i>                                     | 0.21                                                                            | %                   | 0.17 - 0.32     |
| PDW<br><i>Calculated</i>                                     | 17                                                                              | fL                  | 8.3 - 25.0      |
| P-LCR<br><i>Calculated</i>                                   | 19                                                                              | %                   | 18 - 50         |
| P-LCC<br><i>Calculated</i>                                   | 121                                                                             | %                   | 44 - 140        |
| LUC - (Atypical cells)                                       | 3                                                                               | %                   | -               |
| Mentzer Index<br><i>Calculated</i>                           | 20.85                                                                           | %                   | > 13            |
| R.B.C. Morphology<br><i>Microscopy</i>                       | Normocytic<br>Normochromic                                                      | -                   | -               |
| W.B.C. Morphology<br><i>Microscopy</i>                       | Within normal limits                                                            | -                   | -               |
| Platelet Morphology<br><i>Microscopy</i>                     | Adequate on Smear                                                               | -                   | -               |
| Parasite                                                     | NO PARASITE SEEN                                                                |                     |                 |
| Comment                                                      | NORMOCYTIC<br>NORMOCHROMIC<br>BLOOD PICTURE.<br>KINDLY CORRELATE<br>CLINICALLY. |                     |                 |

**Interpretation:**

CBC provides information about red cells, white cells and platelets. Results are useful in the diagnosis of anemia, infections, leukemias, clotting disorders and many other medical conditions.



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI  
 Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301

 928-909-0609

 ccsupport@redcliffelabs.com

 www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

Patient Name : Mr Mr.Dummy  
DOB/Age/Gender : 23 Y/Male  
Patient ID / UHID : 8053280/RCL7247928  
Referred By : Dr. Dr. X  
Sample Type : Whole blood EDTA

Sample Collected : Apr 26, 2024, 01:00 PM  
Report Date : Jun 04, 2024, 01:57 PM.  
Barcode No : HY748008  
Report Status : Final Report



| Test Description | Value(s) | Unit(s) | Reference Range |
|------------------|----------|---------|-----------------|
|------------------|----------|---------|-----------------|

Erythrocyte Sedimentation Rate (ESR)

|                                                             |   |       |        |
|-------------------------------------------------------------|---|-------|--------|
| ESR - Erythrocyte Sedimentation Rate<br>MODIFIED WESTERGREN | 5 | mm/hr | 0 - 10 |
|-------------------------------------------------------------|---|-------|--------|

**Interpretation:**  
ESR is also known as Erythrocyte Sedimentation Rate. An ESR test is used to assess inflammation in the body. Many conditions can cause an abnormal ESR, so an ESR test is typically used with other tests to diagnose and monitor different diseases. An elevated ESR may occur in inflammatory conditions including infection, rheumatoid arthritis ,systemic vasculitis, anemia, multiple myeloma , etc. Low levels are typically seen in congestive heart failure, polycythemia ,sickle cell anemia, hypo fibrinogenemia , etc.

| AGE                | MALE | FEMALE |
|--------------------|------|--------|
| 1 DAY              | 0-2  | 0-2    |
| 2 - 7 DAYS         | 0-4  | 0-4    |
| 8 - 14 DAYS        | 0-17 | 0-17   |
| 15 DAYS - 17 YEARS | 0-20 | 0-20   |
| 18 - 50 YEARS      | 0-10 | 0-12   |
| 51- 60 YEARS       | 0-12 | 0-19   |
| 61 - 70 YEARS      | 0-14 | 0-20   |
| 71 - 100 YEARS     | 0-30 | 0-35   |

**Reference-** Dacie and lewis practical hematology



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI  
Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301

928-909-0609

ccsupport@redcliffelabs.com

www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

|                   |                      |                  |                           |                                                                                                |
|-------------------|----------------------|------------------|---------------------------|------------------------------------------------------------------------------------------------|
| Patient Name      | : Mr Mr.Dummy        | Sample Collected | : Apr 26, 2024, 01:00 PM  | <br>MC-5280 |
| DOB/Age/Gender    | : 23 Y/Male          | Report Date      | : Jun 04, 2024, 01:58 PM. |                                                                                                |
| Patient ID / UHID | : 8053280/RCL7247928 | Barcode No       | : HY748008                |                                                                                                |
| Referred By       | : Dr. Dr. X          | Report Status    | : Final Report            |                                                                                                |
| Sample Type       | : Whole blood EDTA   |                  |                           |                                                                                                |
| Test Description  |                      | Value(s)         | Unit(s)                   | Reference Range                                                                                |

HbA1C (Glycosylated Haemoglobin)

|                                 |        |       |                   |
|---------------------------------|--------|-------|-------------------|
| Glycosylated Hemoglobin (HbA1c) | 5.4    | %     | <5.7              |
| Estimated Average Glucose       | 108.28 | mg/dl | Refer Table Below |

Interpretation:

Interpretation For HbA1c% As per American Diabetes Association (ADA)

| Reference Group                        | HbA1c in %                                                                          |
|----------------------------------------|-------------------------------------------------------------------------------------|
| Non diabetic adults >=18 years         | <5.7                                                                                |
| At risk (Prediabetes)                  | 5.7 - 6.4                                                                           |
| Diagnosing Diabetes                    | >= 6.5                                                                              |
| Therapeutic goals for glycemic control | Age > 19 years<br>Goal of therapy: < 7.0<br>Age < 19 years<br>Goal of therapy: <7.5 |

Note:

1. Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is recently under good control may still have a high concentration of HbA1c. Converse is true for a diabetic previously under good control but now poorly controlled. 2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 7.0 % may not be appropriate

Comments :

HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations ADA criteria for correlation between HbA1c & Mean plasma glucose levels.

| HbA1c(%) | Mean Plasma Glucose (mg/dL) | HbA1c(%) | Mean Plasma Glucose (mg/dL) |
|----------|-----------------------------|----------|-----------------------------|
| 6        | 126                         | 12       | 298                         |
| 8        | 183                         | 14       | 355                         |
| 10       | 240                         | 16       | 413                         |



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI  
Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301

928-909-0609

ccsupport@redcliffelabs.com

www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

|                   |                      |                  |                           |                                                                                     |
|-------------------|----------------------|------------------|---------------------------|-------------------------------------------------------------------------------------|
| Patient Name      | : Mr Mr.Dummy        | Sample Collected | : Apr 26, 2024, 01:00 PM  |  |
| DOB/Age/Gender    | : 23 Y/Male          | Report Date      | : Jun 04, 2024, 01:56 PM. |                                                                                     |
| Patient ID / UHID | : 8053280/RCL7247928 | Barcode No       | : ZD048105                |                                                                                     |
| Referred By       | : Dr. Dr. X          | Report Status    | : Final Report            |                                                                                     |
| Sample Type       | : FLUORIDE F         |                  |                           |                                                                                     |
| Test Description  |                      | Value(s)         | Unit(s)                   | Reference Range                                                                     |

Glucose Fasting (BSF)

|                                                                                                                                                                                                                                                                                                                                                                                                                    |                                        |       |      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|-------|------|
| Glucose Fasting<br><i>Hexokinase</i>                                                                                                                                                                                                                                                                                                                                                                               | 87                                     | mg/dL | <100 |
| <b>Interpretation:</b>                                                                                                                                                                                                                                                                                                                                                                                             |                                        |       |      |
| <b>Status</b>                                                                                                                                                                                                                                                                                                                                                                                                      | <b>Fasting plasma glucose in mg/dL</b> |       |      |
| Normal                                                                                                                                                                                                                                                                                                                                                                                                             | <100                                   |       |      |
| Impaired fasting glucose                                                                                                                                                                                                                                                                                                                                                                                           | 100 - 125                              |       |      |
| Diabetes                                                                                                                                                                                                                                                                                                                                                                                                           | ≥126                                   |       |      |
| <b>Reference</b> : American Diabetes Association                                                                                                                                                                                                                                                                                                                                                                   |                                        |       |      |
| <b>Comment :</b><br>Blood glucose determinations in commonly used as an aid in the diagnosis and treatment of diabetes. Elevated glucose levels (hyperglycemia) may also occur with pancreatic neoplasm, hyperthyroidism, and adrenal cortical hyper function as well as other disorders. Decreased glucose levels (hypoglycemia) may result from excessive insulin therapy insulinoma, or various liver diseases. |                                        |       |      |
| <b>Note</b><br><b>1.</b> The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL or a random / 2 hour plasma glucose value of > or = 200 mg/dL with symptoms of diabetes mellitus.<br><b>2.</b> Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis.                                                                                                       |                                        |       |      |



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI  
Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301

928-909-0609

ccsupport@redcliffelabs.com

www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

Patient Name : Mr Mr.Dummy

DOB/Age/Gender : 23 Y/Male

Patient ID / UHID : 8053280/RCL7247928

Referred By : Dr. Dr. X

Sample Type : Serum

Sample Collected : Apr 26, 2024, 01:00 PM

Report Date : Jun 04, 2024, 01:56 PM.

Barcode No : ZD048106

Report Status : Final Report



| Test Description | Value(s) | Unit(s) | Reference Range |
|------------------|----------|---------|-----------------|
|------------------|----------|---------|-----------------|

Lipid Profile

|                                                             |      |       |      |
|-------------------------------------------------------------|------|-------|------|
| Total Cholesterol<br><i>Enzymatic - Cholesterol Oxidase</i> | 187  | mg/dL | <200 |
| Triglycerides<br><i>Colorimetric - Lip/Glycerol Kinase</i>  | 135  | mg/dL | <150 |
| HDL Cholesterol<br><i>Phosphotungstic acid- Enzymatic</i>   | 61   | mg/dL | > 40 |
| Non HDL Cholesterol<br><i>Calculated</i>                    | 126  | mg/dL | <130 |
| LDL Cholesterol<br><i>Calculated</i>                        | 99   | mg/dL | <100 |
| V.L.D.L Cholesterol<br><i>Calculated</i>                    | 27   | mg/dL | < 30 |
| Chol/HDL Ratio<br><i>Calculated</i>                         | 3.07 | Ratio | -    |
| HDL/ LDL Ratio<br><i>Calculated</i>                         | 0.62 | Ratio | -    |
| LDL/HDL Ratio<br><i>Calculated</i>                          | 1.62 | Ratio | -    |

Interpretation:

Lipid level assessments must be made following 9 to 12 hours of fasting, otherwise assay results might lead to erroneous interpretation. NCEP recommends of 3 different samples to be drawn at intervals of 1 week for harmonizing biological variables that might be encountered in single assays.

| National Lipid Association Recommendations (NLA-2014) | Total Cholesterol (mg/dL) | Triglyceride (mg/dL) | LDL Cholesterol (mg/dL) | Non HDL Cholesterol (mg/dL) |
|-------------------------------------------------------|---------------------------|----------------------|-------------------------|-----------------------------|
| Optimal                                               | <200                      | <150                 | <100                    | <130                        |
| Above Optimal                                         |                           |                      | 100-129                 | 130 - 159                   |
| Borderline High                                       | 200-239                   | 150-199              | 130-159                 | 160 - 189                   |
| High                                                  | >=240                     | 200-499              | 160-189                 | 190 - 219                   |
| Very High                                             | -                         | >=500                | >=190                   | >=220                       |

| HDL Cholesterol |      |
|-----------------|------|
| Low             | High |
| <40             | >=60 |

Risk Stratification for ASCVD (Atherosclerotic Cardiovascular Disease) by Lipid Association of India.

|                    |                                                                                                                                       |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------|
| Risk Category      | A. CAD with > 1 feature of high risk group                                                                                            |
| Extreme risk group | B. CAD with >1 feature of very high risk group of recurrent ACS (within 1 year) despite LDL-C <or = 50 mg/dl or poly vascular disease |



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI  
Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301

928-909-0609

ccsupport@redcliffelabs.com

www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

Patient Name : Mr Mr.Dummy  
 DOB/Age/Gender : 23 Y/Male  
 Patient ID / UHID : 8053280/RCL7247928  
 Referred By : Dr. Dr. X  
 Sample Type : Serum

Sample Collected : Apr 26, 2024, 01:00 PM  
 Report Date : Jun 04, 2024, 01:56 PM.  
 Barcode No : ZD048106  
 Report Status : Final Report



| Test Description                                                  |  | Value(s)                                                                                                                                                                                                                                                                                  | Unit(s) | Reference Range |
|-------------------------------------------------------------------|--|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|-----------------|
| Very High Risk                                                    |  | 1.Established ASCVD 2.Diabetes with 2 major risk factors of evidence of end organ damage 3. Familial Homozygous Hypercholesterolemia                                                                                                                                                      |         |                 |
| High Risk                                                         |  | 1. Three major ASCVD risk factors 2. Diabetes with 1 major risk factor or no evidence of end organ damage 3. CHD stage 3B or 4. 4 LDL >190 mg/dl 5. Extreme of a single risk factor 6. Coronary Artery Calcium - CAC > 300 AU 7. Lipoprotein a >= 50 mg/dl 8. Non stenotic carotid plaque |         |                 |
| Moderate Risk                                                     |  | 2 major ASCVD risk factors                                                                                                                                                                                                                                                                |         |                 |
| Low Risk                                                          |  | 0-1 major ASCVD risk factors                                                                                                                                                                                                                                                              |         |                 |
| Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors |  |                                                                                                                                                                                                                                                                                           |         |                 |
| 1. Age >=45 years in Males & >= 55 years in Females               |  | 3. Current Cigarette smoking or tobacco use                                                                                                                                                                                                                                               |         |                 |
| 2. Family history of premature ASCVD                              |  | 4. High blood pressure                                                                                                                                                                                                                                                                    |         |                 |
| 5. Low HDL                                                        |  |                                                                                                                                                                                                                                                                                           |         |                 |

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by Lipid Association of India in 2020.

| Risk Group                    | Treatment Goals              |                              | Consider Drug Therapy |                 |
|-------------------------------|------------------------------|------------------------------|-----------------------|-----------------|
|                               | LDL-C (mg/dl)                | Non-HDL (mg/dl)              | LDL-C (mg/dl)         | Non-HDL (mg/dl) |
| Extreme Risk Group Category A | <50 (Optional goal <OR = 30) | <80 (Optional goal <OR = 60) | >OR = 50              | >OR = 80        |
| Extreme Risk Group Category B | >OR = 30                     | >OR = 60                     | > 30                  | > 60            |
| Very High Risk                | <50                          | <80                          | >OR = 50              | >OR = 80        |
| High Risk                     | <70                          | <100                         | >OR = 70              | >OR = 100       |
| Moderate Risk                 | <100                         | <130                         | >OR = 100             | >OR = 130       |
| Low Risk                      | <100                         | <130                         | >OR = 130*            | >OR = 160       |

\* After an adequate non-pharmacological intervention for at least 3 months.

References : Management of Dyslipidaemia for the Prevention of Stroke : Clinical practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology,2022,20,134-155.



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI  
 Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301

928-909-0609

ccsupport@redcliffelabs.com

www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

|                   |                      |                  |                           |                                                                                                |
|-------------------|----------------------|------------------|---------------------------|------------------------------------------------------------------------------------------------|
| Patient Name      | : Mr Mr.Dummy        | Sample Collected | : Apr 26, 2024, 01:00 PM  | <br>MC-5280 |
| DOB/Age/Gender    | : 23 Y/Male          | Report Date      | : Jun 04, 2024, 01:56 PM. |                                                                                                |
| Patient ID / UHID | : 8053280/RCL7247928 | Barcode No       | : ZD048106                |                                                                                                |
| Referred By       | : Dr. Dr. X          | Report Status    | : Final Report            |                                                                                                |
| Sample Type       | : Serum              |                  |                           |                                                                                                |
| Test Description  | Value(s)             | Unit(s)          | Reference Range           |                                                                                                |

Vitamin D 25 Hydroxy

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |    |       |                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|-------|------------------------|
| Vitamin D 25 - Hydroxy<br>ECLIA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 76 | ng/mL | Deficiency : <30 ng/mL |
| <b>Interpretation:</b><br>25-Hydroxy vitamin D represents the main body reservoir and transport form. Mild to moderate deficiency is associated with Osteoporosis / Secondary Hyperparathyroidism while severe deficiency causes Rickets in children and Osteomalacia in adults. Prevalence of Vitamin D deficiency is approximately >50% specially in the elderly. This assay is useful for diagnosis of vitamin D deficiency and Hypervitaminosis D. It is also used for differential diagnosis of causes of Rickets & Osteomalacia and for monitoring Vitamin D replacement therapy. |    |       |                        |



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI  
Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301

928-909-0609

ccsupport@redcliffelabs.com

www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

| Patient Name      | : Mr Mr.Dummy        | Sample Collected | : Apr 26, 2024, 01:00 PM  | <br>MC-5280 |
|-------------------|----------------------|------------------|---------------------------|------------------------------------------------------------------------------------------------|
| DOB/Age/Gender    | : 23 Y/Male          | Report Date      | : Jun 04, 2024, 01:56 PM. |                                                                                                |
| Patient ID / UHID | : 8053280/RCL7247928 | Barcode No       | : ZD048106                |                                                                                                |
| Referred By       | : Dr. Dr. X          | Report Status    | : Final Report            |                                                                                                |
| Sample Type       | : Serum              |                  |                           |                                                                                                |
| Test Description  | Value(s)             | Unit(s)          | Reference Range           |                                                                                                |

Immunoglobulin E (IgE Total)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |    |       |       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|-------|-------|
| IMMUNOGLOBULIN IgE TOTAL SERUM<br>ECLIA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 76 | IU/mL | 0-100 |
| <p><b>Interpretation:</b><br/>The level of serum IgE rises during childhood and reaches adult levels during the teens. IgE is the mediator of the allergic response. Patients with atopic disease, including allergic asthma, allergic rhinitis, and atopic dermatitis commonly have moderately elevated serum IgE levels. Total serum IgE levels may also be elevated in the presence of some clinical conditions that are not related to allergy. These clinical conditions include parasitic infections, immunodeficiency states, autoimmune diseases, Hodgkins disease, bronchopulmonary aspergillosis, IgE myeloma, and Sezary syndrome.</p> |    |       |       |

\*\*\* End Of Report \*\*\*

**Disclaimer:** Method given in report are only indicative and can be changed depending upon type of machine and kit available at time of testing.

**Not all tests at all locations are under NABL scope. Availability of tests under NABL scope varies from lab to lab.**



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI  
Processing Lab :- Redcliffe Lifetech Pvt. Ltd., H-55, Sector-63, Noida, Uttar Pradesh - 201301

928-909-0609

ccsupport@redcliffelabs.com

www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

# Terms and Conditions of Reporting

1. The presented findings in the Reports are intended solely for informational and interpretational purposes by the referring physician or other qualified medical professionals possessing a comprehensive understanding of reporting units, reference ranges, and technological limitations. The laboratory shall not be held liable for any interpretation or misinterpretation of the results, nor for any consequential or incidental damages arising from such interpretation.
2. It is to be presumed that the tests performed pertain to the specimen/sample attributed to the Customer's name or identification. It is presumed that the verification particulars have been cleared out by the customer or his/her representation at the point of generation of said specimen / sample. It is hereby clarified that the reports furnished are restricted solely to the given specimen only.
3. It is to be noted that variations in results may occur between different laboratories and over time, even for the same parameter for the same Customer. The assays are performed and conducted in accordance with standard procedures, and the reported outcomes are contingent on the specific individual assay methods and equipment(s) used, as well as the quality of the received specimen.
4. This report shall not be deemed valid or admissible for any medico-legal purposes.
5. The Customers assume full responsibility for apprising the Company of any factors that may impact the test finding. These factors, among others, includes dietary intake, alcohol, or medication / drug(s) consumption, or fasting. This list of factors is only representative and not exhaustive.

---

## DISCLAIMER

This is a sample report provided for demonstration purposes only and does not represent an actual patient report. Test results, reference ranges, methodologies, instrumentation, and report formats may vary depending on the laboratory performing the test. The format and representation shown are indicative of reports generated by the National Reference Laboratory of Redcliffe Labs, Noida. This sample report should not be used for medical interpretation, diagnosis, or treatment decisions.